Market Cap (In USD)
104.06 Million
Revenue (In USD)
-
Net Income (In USD)
-71.16 Million
Avg. Volume
516.66 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.385-7.795
- PE
- -1.0
- EPS
- -1.62
- Beta Value
- 1.54
- ISIN
- US45790W1080
- CUSIP
- 45790W108
- CIK
- 1693011
- Shares
- 64240200.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Douglas A. Treco Ph.D.
- Employee Count
- -
- Website
- https://www.inozyme.com
- Ipo Date
- 2020-07-24
- Details
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
More Stocks
-
QYOUFQYOU Media Inc.
QYOUF
-
RNT
-
300308Zhongji Innolight Co., Ltd.
300308
-
HABITAT
-
ICCHICC Holdings, Inc.
ICCH
-
WLFD
-
301163
-
1245